Evofem Biosciences, Inc.

For the period ended Dec 31, 2024. Filed Mar 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 24, 2025

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data)

	Years Ended December 31,
	2024	2023
Product sales, net	$19,363	$18,218
Operating Expenses:
Cost of goods sold	3,834	6,512
Amortization of intangible asset	619	-
Research and development	1,845	2,939
Selling and marketing	9,176	11,664
General and administrative	11,565	14,950
Total operating expenses	27,039	36,065
Loss from operations	(7,676)	(17,847)
Other income (expense):
Interest income	16	31
Other expense, net	(2,575)	(2,628)
Loss on issuance of financial instruments	(3,300)	(6,776)
Gain on debt extinguishment, net	977	75,337
Change in fair value of financial instruments	3,698	4,879
Total other income (expense), net	(1,184)	70,843
Income (loss) before income tax	(8,860)	52,996
Income tax expense	-	(17)
Net income (loss)	(8,860)	52,979
Convertible preferred stock deemed dividends	(105)	(2,984)
Net income (loss) attributable to common stockholders	$(8,965)	$49,995
Net income (loss) per share attributable to common stockholders:
Basic (Note 2)	$(0.12)	$10.36
Diluted (Note 2)	$(0.12)	$0.05
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:
Basic	75,195,615	4,826,763
Diluted	75,195,615	984,038,574

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.